Profiling of Humoral Response to Influenza A(H1N1)pdm09 Infection and Vaccination Measured by a Protein Microarray in Persons with and without History of Seasonal Vaccination
Identifieur interne : 000B52 ( Pmc/Corpus ); précédent : 000B51; suivant : 000B53Profiling of Humoral Response to Influenza A(H1N1)pdm09 Infection and Vaccination Measured by a Protein Microarray in Persons with and without History of Seasonal Vaccination
Auteurs : Elisabeth G. W. Huijskens ; Johan Reimerink ; Paul G. H. Mulder ; Janko Van Beek ; Adam Meijer ; Erwin De Bruin ; Ingrid Friesema ; Menno D. De Jong ; Guus F. Rimmelzwaan ; Marcel F. Peeters ; John W. A. Rossen ; Marion KoopmansSource :
- PLoS ONE [ 1932-6203 ] ; 2013.
Abstract
The influence of prior seasonal influenza vaccination on the antibody response produced by natural infection or vaccination is not well understood.
We compared the profiles of antibody responses of 32 naturally infected subjects and 98 subjects vaccinated with a 2009 influenza A(H1N1) monovalent MF59-adjuvanted vaccine (Focetria®, Novartis), with and without a history of seasonal influenza vaccination. Antibodies were measured by hemagglutination inhibition (HI) assay for influenza A(H1N1)pdm09 and by protein microarray (PA) using the HA1 subunit for seven recent and historic H1, H2 and H3 influenza viruses, and three avian influenza viruses. Serum samples for the infection group were taken at the moment of collection of the diagnostic sample, 10 days and 30 days after onset of influenza symptoms. For the vaccination group, samples were drawn at baseline, 3 weeks after the first vaccination and 5 weeks after the second vaccination.
We showed that subjects with a history of seasonal vaccination generally exhibited higher baseline titers for the various HA1 antigens than subjects without a seasonal vaccination history. Infection and pandemic influenza vaccination responses in persons with a history of seasonal vaccination were skewed towards historic antigens.
Seasonal vaccination is of significant influence on the antibody response to subsequent infection and vaccination, and further research is needed to understand the effect of annual vaccination on protective immunity.
Url:
DOI: 10.1371/journal.pone.0054890
PubMed: 23365683
PubMed Central: 3554683
Links to Exploration step
PMC:3554683Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Profiling of Humoral Response to Influenza A(H1N1)pdm09 Infection and Vaccination Measured by a Protein Microarray in Persons with and without History of Seasonal Vaccination</title><author><name sortKey="Huijskens, Elisabeth G W" sort="Huijskens, Elisabeth G W" uniqKey="Huijskens E" first="Elisabeth G. W." last="Huijskens">Elisabeth G. W. Huijskens</name><affiliation><nlm:aff id="aff1"><addr-line>Laboratory of Medical Microbiology and Immunology, St. Elisabeth Hospital, Tilburg, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Reimerink, Johan" sort="Reimerink, Johan" uniqKey="Reimerink J" first="Johan" last="Reimerink">Johan Reimerink</name><affiliation><nlm:aff id="aff2"><addr-line>National Institute of Public Health and the Environment, RIVM, Bilthoven, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Mulder, Paul G H" sort="Mulder, Paul G H" uniqKey="Mulder P" first="Paul G. H." last="Mulder">Paul G. H. Mulder</name><affiliation><nlm:aff id="aff3"><addr-line>Amphia Academy, Amphia Hospital, Breda, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Van Beek, Janko" sort="Van Beek, Janko" uniqKey="Van Beek J" first="Janko" last="Van Beek">Janko Van Beek</name><affiliation><nlm:aff id="aff2"><addr-line>National Institute of Public Health and the Environment, RIVM, Bilthoven, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Meijer, Adam" sort="Meijer, Adam" uniqKey="Meijer A" first="Adam" last="Meijer">Adam Meijer</name><affiliation><nlm:aff id="aff2"><addr-line>National Institute of Public Health and the Environment, RIVM, Bilthoven, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="De Bruin, Erwin" sort="De Bruin, Erwin" uniqKey="De Bruin E" first="Erwin" last="De Bruin">Erwin De Bruin</name><affiliation><nlm:aff id="aff2"><addr-line>National Institute of Public Health and the Environment, RIVM, Bilthoven, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Friesema, Ingrid" sort="Friesema, Ingrid" uniqKey="Friesema I" first="Ingrid" last="Friesema">Ingrid Friesema</name><affiliation><nlm:aff id="aff2"><addr-line>National Institute of Public Health and the Environment, RIVM, Bilthoven, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="De Jong, Menno D" sort="De Jong, Menno D" uniqKey="De Jong M" first="Menno D." last="De Jong">Menno D. De Jong</name><affiliation><nlm:aff id="aff4"><addr-line>Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Rimmelzwaan, Guus F" sort="Rimmelzwaan, Guus F" uniqKey="Rimmelzwaan G" first="Guus F." last="Rimmelzwaan">Guus F. Rimmelzwaan</name><affiliation><nlm:aff id="aff5"><addr-line>Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Peeters, Marcel F" sort="Peeters, Marcel F" uniqKey="Peeters M" first="Marcel F." last="Peeters">Marcel F. Peeters</name><affiliation><nlm:aff id="aff1"><addr-line>Laboratory of Medical Microbiology and Immunology, St. Elisabeth Hospital, Tilburg, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Rossen, John W A" sort="Rossen, John W A" uniqKey="Rossen J" first="John W. A." last="Rossen">John W. A. Rossen</name><affiliation><nlm:aff id="aff1"><addr-line>Laboratory of Medical Microbiology and Immunology, St. Elisabeth Hospital, Tilburg, The Netherlands</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff6"><addr-line>Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Koopmans, Marion" sort="Koopmans, Marion" uniqKey="Koopmans M" first="Marion" last="Koopmans">Marion Koopmans</name><affiliation><nlm:aff id="aff2"><addr-line>National Institute of Public Health and the Environment, RIVM, Bilthoven, The Netherlands</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff5"><addr-line>Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands</addr-line></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23365683</idno><idno type="pmc">3554683</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554683</idno><idno type="RBID">PMC:3554683</idno><idno type="doi">10.1371/journal.pone.0054890</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">000B52</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000B52</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Profiling of Humoral Response to Influenza A(H1N1)pdm09 Infection and Vaccination Measured by a Protein Microarray in Persons with and without History of Seasonal Vaccination</title><author><name sortKey="Huijskens, Elisabeth G W" sort="Huijskens, Elisabeth G W" uniqKey="Huijskens E" first="Elisabeth G. W." last="Huijskens">Elisabeth G. W. Huijskens</name><affiliation><nlm:aff id="aff1"><addr-line>Laboratory of Medical Microbiology and Immunology, St. Elisabeth Hospital, Tilburg, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Reimerink, Johan" sort="Reimerink, Johan" uniqKey="Reimerink J" first="Johan" last="Reimerink">Johan Reimerink</name><affiliation><nlm:aff id="aff2"><addr-line>National Institute of Public Health and the Environment, RIVM, Bilthoven, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Mulder, Paul G H" sort="Mulder, Paul G H" uniqKey="Mulder P" first="Paul G. H." last="Mulder">Paul G. H. Mulder</name><affiliation><nlm:aff id="aff3"><addr-line>Amphia Academy, Amphia Hospital, Breda, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Van Beek, Janko" sort="Van Beek, Janko" uniqKey="Van Beek J" first="Janko" last="Van Beek">Janko Van Beek</name><affiliation><nlm:aff id="aff2"><addr-line>National Institute of Public Health and the Environment, RIVM, Bilthoven, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Meijer, Adam" sort="Meijer, Adam" uniqKey="Meijer A" first="Adam" last="Meijer">Adam Meijer</name><affiliation><nlm:aff id="aff2"><addr-line>National Institute of Public Health and the Environment, RIVM, Bilthoven, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="De Bruin, Erwin" sort="De Bruin, Erwin" uniqKey="De Bruin E" first="Erwin" last="De Bruin">Erwin De Bruin</name><affiliation><nlm:aff id="aff2"><addr-line>National Institute of Public Health and the Environment, RIVM, Bilthoven, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Friesema, Ingrid" sort="Friesema, Ingrid" uniqKey="Friesema I" first="Ingrid" last="Friesema">Ingrid Friesema</name><affiliation><nlm:aff id="aff2"><addr-line>National Institute of Public Health and the Environment, RIVM, Bilthoven, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="De Jong, Menno D" sort="De Jong, Menno D" uniqKey="De Jong M" first="Menno D." last="De Jong">Menno D. De Jong</name><affiliation><nlm:aff id="aff4"><addr-line>Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Rimmelzwaan, Guus F" sort="Rimmelzwaan, Guus F" uniqKey="Rimmelzwaan G" first="Guus F." last="Rimmelzwaan">Guus F. Rimmelzwaan</name><affiliation><nlm:aff id="aff5"><addr-line>Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Peeters, Marcel F" sort="Peeters, Marcel F" uniqKey="Peeters M" first="Marcel F." last="Peeters">Marcel F. Peeters</name><affiliation><nlm:aff id="aff1"><addr-line>Laboratory of Medical Microbiology and Immunology, St. Elisabeth Hospital, Tilburg, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Rossen, John W A" sort="Rossen, John W A" uniqKey="Rossen J" first="John W. A." last="Rossen">John W. A. Rossen</name><affiliation><nlm:aff id="aff1"><addr-line>Laboratory of Medical Microbiology and Immunology, St. Elisabeth Hospital, Tilburg, The Netherlands</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff6"><addr-line>Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Koopmans, Marion" sort="Koopmans, Marion" uniqKey="Koopmans M" first="Marion" last="Koopmans">Marion Koopmans</name><affiliation><nlm:aff id="aff2"><addr-line>National Institute of Public Health and the Environment, RIVM, Bilthoven, The Netherlands</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff5"><addr-line>Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands</addr-line></nlm:aff></affiliation></author></analytic><series><title level="j">PLoS ONE</title><idno type="eISSN">1932-6203</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background</title><p>The influence of prior seasonal influenza vaccination on the antibody response produced by natural infection or vaccination is not well understood.</p></sec><sec><title>Methods</title><p>We compared the profiles of antibody responses of 32 naturally infected subjects and 98 subjects vaccinated with a 2009 influenza A(H1N1) monovalent MF59-adjuvanted vaccine (Focetria®, Novartis), with and without a history of seasonal influenza vaccination. Antibodies were measured by hemagglutination inhibition (HI) assay for influenza A(H1N1)pdm09 and by protein microarray (PA) using the HA1 subunit for seven recent and historic H1, H2 and H3 influenza viruses, and three avian influenza viruses. Serum samples for the infection group were taken at the moment of collection of the diagnostic sample, 10 days and 30 days after onset of influenza symptoms. For the vaccination group, samples were drawn at baseline, 3 weeks after the first vaccination and 5 weeks after the second vaccination.</p></sec><sec><title>Results</title><p>We showed that subjects with a history of seasonal vaccination generally exhibited higher baseline titers for the various HA1 antigens than subjects without a seasonal vaccination history. Infection and pandemic influenza vaccination responses in persons with a history of seasonal vaccination were skewed towards historic antigens.</p></sec><sec><title>Conclusions</title><p>Seasonal vaccination is of significant influence on the antibody response to subsequent infection and vaccination, and further research is needed to understand the effect of annual vaccination on protective immunity.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Jia, N" uniqKey="Jia N">N Jia</name></author><author><name sortKey="De Vlas, Sj" uniqKey="De Vlas S">SJ de Vlas</name></author><author><name sortKey="Liu, Yx" uniqKey="Liu Y">YX Liu</name></author><author><name sortKey="Zhang, Js" uniqKey="Zhang J">JS Zhang</name></author><author><name sortKey="Zhan, L" uniqKey="Zhan L">L Zhan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Russell, Rj" uniqKey="Russell R">RJ Russell</name></author><author><name sortKey="Burns, Wh" uniqKey="Burns W">WH Burns</name></author><author><name sortKey="White, Do" uniqKey="White D">DO White</name></author><author><name sortKey="Anders, Em" uniqKey="Anders E">EM Anders</name></author><author><name sortKey="Ward, Cw" uniqKey="Ward C">CW Ward</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Friesen, Rh" uniqKey="Friesen R">RH Friesen</name></author><author><name sortKey="Koudstaal, W" uniqKey="Koudstaal W">W Koudstaal</name></author><author><name sortKey="Koldijk, Mh" uniqKey="Koldijk M">MH Koldijk</name></author><author><name sortKey="Weverling, Gj" uniqKey="Weverling G">GJ Weverling</name></author><author><name sortKey="Brakenhoff, Jp" uniqKey="Brakenhoff J">JP Brakenhoff</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ekiert, Dc" uniqKey="Ekiert D">DC Ekiert</name></author><author><name sortKey="Bhabha, G" uniqKey="Bhabha G">G Bhabha</name></author><author><name sortKey="Elsliger, Ma" uniqKey="Elsliger M">MA Elsliger</name></author><author><name sortKey="Friesen, Rh" uniqKey="Friesen R">RH Friesen</name></author><author><name sortKey="Jongeneelen, M" uniqKey="Jongeneelen M">M Jongeneelen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hancock, K" uniqKey="Hancock K">K Hancock</name></author><author><name sortKey="Veguilla, V" uniqKey="Veguilla V">V Veguilla</name></author><author><name sortKey="Lu, X" uniqKey="Lu X">X Lu</name></author><author><name sortKey="Zhong, W" uniqKey="Zhong W">W Zhong</name></author><author><name sortKey="Butler, En" uniqKey="Butler E">EN Butler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Steens, A" uniqKey="Steens A">A Steens</name></author><author><name sortKey="Waaijenborg, S" uniqKey="Waaijenborg S">S Waaijenborg</name></author><author><name sortKey="Teunis, Pf" uniqKey="Teunis P">PF Teunis</name></author><author><name sortKey="Reimerink, Jh" uniqKey="Reimerink J">JH Reimerink</name></author><author><name sortKey="Meijer, A" uniqKey="Meijer A">A Meijer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wrammert, J" uniqKey="Wrammert J">J Wrammert</name></author><author><name sortKey="Koutsonanos, D" uniqKey="Koutsonanos D">D Koutsonanos</name></author><author><name sortKey="Li, Gm" uniqKey="Li G">GM Li</name></author><author><name sortKey="Edupuganti, S" uniqKey="Edupuganti S">S Edupuganti</name></author><author><name sortKey="Sui, J" uniqKey="Sui J">J Sui</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Corti, D" uniqKey="Corti D">D Corti</name></author><author><name sortKey="Suguitan, Al" uniqKey="Suguitan A">AL Suguitan</name></author><author><name sortKey="Pinna, D" uniqKey="Pinna D">D Pinna</name></author><author><name sortKey="Silacci, C" uniqKey="Silacci C">C Silacci</name></author><author><name sortKey="Fernandez Rodriguez, Bm" uniqKey="Fernandez Rodriguez B">BM Fernandez-Rodriguez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ding, H" uniqKey="Ding H">H Ding</name></author><author><name sortKey="Tsai, C" uniqKey="Tsai C">C Tsai</name></author><author><name sortKey="Zhou, F" uniqKey="Zhou F">F Zhou</name></author><author><name sortKey="Buchy, P" uniqKey="Buchy P">P Buchy</name></author><author><name sortKey="Deubel, V" uniqKey="Deubel V">V Deubel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bodewes, R" uniqKey="Bodewes R">R Bodewes</name></author><author><name sortKey="Kreijtz, Jh" uniqKey="Kreijtz J">JH Kreijtz</name></author><author><name sortKey="Geelhoed Mieras, Mm" uniqKey="Geelhoed Mieras M">MM Geelhoed-Mieras</name></author><author><name sortKey="Van Amerongen, G" uniqKey="Van Amerongen G">G van Amerongen</name></author><author><name sortKey="Verburgh, Rj" uniqKey="Verburgh R">RJ Verburgh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Huijskens, E" uniqKey="Huijskens E">E Huijskens</name></author><author><name sortKey="Rossen, J" uniqKey="Rossen J">J Rossen</name></author><author><name sortKey="Mulder, P" uniqKey="Mulder P">P Mulder</name></author><author><name sortKey="Van Beek, R" uniqKey="Van Beek R">R van Beek</name></author><author><name sortKey="Van Vugt, H" uniqKey="Van Vugt H">H van Vugt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Jong, Jc" uniqKey="De Jong J">JC de Jong</name></author><author><name sortKey="Palache, Am" uniqKey="Palache A">AM Palache</name></author><author><name sortKey="Beyer, We" uniqKey="Beyer W">WE Beyer</name></author><author><name sortKey="Rimmelzwaan, Gf" uniqKey="Rimmelzwaan G">GF Rimmelzwaan</name></author><author><name sortKey="Boon, Ac" uniqKey="Boon A">AC Boon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alvarez, Mm" uniqKey="Alvarez M">MM Alvarez</name></author><author><name sortKey="Lopez Pacheco, F" uniqKey="Lopez Pacheco F">F Lopez-Pacheco</name></author><author><name sortKey="Aguilar Yanez, Jm" uniqKey="Aguilar Yanez J">JM Aguilar-Yanez</name></author><author><name sortKey="Portillo Lara, R" uniqKey="Portillo Lara R">R Portillo-Lara</name></author><author><name sortKey="Mendoza Ochoa, Gi" uniqKey="Mendoza Ochoa G">GI Mendoza-Ochoa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Koopmans, M" uniqKey="Koopmans M">M Koopmans</name></author><author><name sortKey="De Bruin, E" uniqKey="De Bruin E">E de Bruin</name></author><author><name sortKey="Godeke, Gj" uniqKey="Godeke G">GJ Godeke</name></author><author><name sortKey="Friesema, I" uniqKey="Friesema I">I Friesema</name></author><author><name sortKey="Van Gageldonk, R" uniqKey="Van Gageldonk R">R van Gageldonk</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Friesema, Ih" uniqKey="Friesema I">IH Friesema</name></author><author><name sortKey="Meijer, A" uniqKey="Meijer A">A Meijer</name></author><author><name sortKey="Van Gageldonk Lafeber, Ab" uniqKey="Van Gageldonk Lafeber A">AB van Gageldonk-Lafeber</name></author><author><name sortKey="Van Der Lubben, M" uniqKey="Van Der Lubben M">M van der Lubben</name></author><author><name sortKey="Van Beek, J" uniqKey="Van Beek J">J van Beek</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Couch, Rb" uniqKey="Couch R">RB Couch</name></author><author><name sortKey="Atmar, Rl" uniqKey="Atmar R">RL Atmar</name></author><author><name sortKey="Franco, Lm" uniqKey="Franco L">LM Franco</name></author><author><name sortKey="Quarles, Jm" uniqKey="Quarles J">JM Quarles</name></author><author><name sortKey="Nino, D" uniqKey="Nino D">D Nino</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Garcia Garcia, L" uniqKey="Garcia Garcia L">L Garcia-Garcia</name></author><author><name sortKey="Valdespino Gomez, Jl" uniqKey="Valdespino Gomez J">JL Valdespino-Gomez</name></author><author><name sortKey="Lazcano Ponce, E" uniqKey="Lazcano Ponce E">E Lazcano-Ponce</name></author><author><name sortKey="Jimenez Corona, A" uniqKey="Jimenez Corona A">A Jimenez-Corona</name></author><author><name sortKey="Higuera Iglesias, A" uniqKey="Higuera Iglesias A">A Higuera-Iglesias</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Johns, Mc" uniqKey="Johns M">MC Johns</name></author><author><name sortKey="Eick, Aa" uniqKey="Eick A">AA Eick</name></author><author><name sortKey="Blazes, Dl" uniqKey="Blazes D">DL Blazes</name></author><author><name sortKey="Lee, Se" uniqKey="Lee S">SE Lee</name></author><author><name sortKey="Perdue, Cl" uniqKey="Perdue C">CL Perdue</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grebe, Km" uniqKey="Grebe K">KM Grebe</name></author><author><name sortKey="Yewdell, Jw" uniqKey="Yewdell J">JW Yewdell</name></author><author><name sortKey="Bennink, Jr" uniqKey="Bennink J">JR Bennink</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fang, Y" uniqKey="Fang Y">Y Fang</name></author><author><name sortKey="Banner, D" uniqKey="Banner D">D Banner</name></author><author><name sortKey="Kelvin, Aa" uniqKey="Kelvin A">AA Kelvin</name></author><author><name sortKey="Huang, Ss" uniqKey="Huang S">SS Huang</name></author><author><name sortKey="Paige, Cj" uniqKey="Paige C">CJ Paige</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hillaire, Ml" uniqKey="Hillaire M">ML Hillaire</name></author><author><name sortKey="Van Trierum, Se" uniqKey="Van Trierum S">SE van Trierum</name></author><author><name sortKey="Kreijtz, Jh" uniqKey="Kreijtz J">JH Kreijtz</name></author><author><name sortKey="Bodewes, R" uniqKey="Bodewes R">R Bodewes</name></author><author><name sortKey="Geelhoed Mieras, Mm" uniqKey="Geelhoed Mieras M">MM Geelhoed-Mieras</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Laurie, Kl" uniqKey="Laurie K">KL Laurie</name></author><author><name sortKey="Carolan, La" uniqKey="Carolan L">LA Carolan</name></author><author><name sortKey="Middleton, D" uniqKey="Middleton D">D Middleton</name></author><author><name sortKey="Lowther, S" uniqKey="Lowther S">S Lowther</name></author><author><name sortKey="Kelso, A" uniqKey="Kelso A">A Kelso</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bodewes, R" uniqKey="Bodewes R">R Bodewes</name></author><author><name sortKey="Kreijtz, Jh" uniqKey="Kreijtz J">JH Kreijtz</name></author><author><name sortKey="Rimmelzwaan, Gf" uniqKey="Rimmelzwaan G">GF Rimmelzwaan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bodewes, R" uniqKey="Bodewes R">R Bodewes</name></author><author><name sortKey="Fraaij, Pl" uniqKey="Fraaij P">PL Fraaij</name></author><author><name sortKey="Geelhoed Mieras, Mm" uniqKey="Geelhoed Mieras M">MM Geelhoed-Mieras</name></author><author><name sortKey="Van Baalen, Ca" uniqKey="Van Baalen C">CA van Baalen</name></author><author><name sortKey="Tiddens, Ha" uniqKey="Tiddens H">HA Tiddens</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bodewes, R" uniqKey="Bodewes R">R Bodewes</name></author><author><name sortKey="De Mutsert, G" uniqKey="De Mutsert G">G de Mutsert</name></author><author><name sortKey="Van Der Klis, Fr" uniqKey="Van Der Klis F">FR van der Klis</name></author><author><name sortKey="Ventresca, M" uniqKey="Ventresca M">M Ventresca</name></author><author><name sortKey="Wilks, S" uniqKey="Wilks S">S Wilks</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gioia, C" uniqKey="Gioia C">C Gioia</name></author><author><name sortKey="Castilletti, C" uniqKey="Castilletti C">C Castilletti</name></author><author><name sortKey="Tempestilli, M" uniqKey="Tempestilli M">M Tempestilli</name></author><author><name sortKey="Piacentini, P" uniqKey="Piacentini P">P Piacentini</name></author><author><name sortKey="Bordi, L" uniqKey="Bordi L">L Bordi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Skowronski, Dm" uniqKey="Skowronski D">DM Skowronski</name></author><author><name sortKey="De Serres, G" uniqKey="De Serres G">G De Serres</name></author><author><name sortKey="Crowcroft, Ns" uniqKey="Crowcroft N">NS Crowcroft</name></author><author><name sortKey="Janjua, Nz" uniqKey="Janjua N">NZ Janjua</name></author><author><name sortKey="Boulianne, N" uniqKey="Boulianne N">N Boulianne</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Skowronski, Dm" uniqKey="Skowronski D">DM Skowronski</name></author><author><name sortKey="Hottes, Ts" uniqKey="Hottes T">TS Hottes</name></author><author><name sortKey="Mcelhaney, Je" uniqKey="Mcelhaney J">JE McElhaney</name></author><author><name sortKey="Janjua, Nz" uniqKey="Janjua N">NZ Janjua</name></author><author><name sortKey="Sabaiduc, S" uniqKey="Sabaiduc S">S Sabaiduc</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23365683</article-id><article-id pub-id-type="pmc">3554683</article-id><article-id pub-id-type="publisher-id">PONE-D-12-19968</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0054890</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Computational Biology</subject><subj-group><subject>Microarrays</subject></subj-group></subj-group><subj-group><subject>Immunology</subject><subj-group><subject>Immunity</subject><subj-group><subject>Humoral Immunity</subject></subj-group></subj-group><subj-group><subject>Immune Response</subject></subj-group></subj-group><subj-group><subject>Microbiology</subject><subj-group><subject>Immunity</subject><subj-group><subject>Humoral Immunity</subject></subj-group></subj-group><subj-group><subject>Virology</subject><subj-group><subject>Viral Vaccines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Viral Diseases</subject><subj-group><subject>Influenza</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Profiling of Humoral Response to Influenza A(H1N1)pdm09 Infection and Vaccination Measured by a Protein Microarray in Persons with and without History of Seasonal Vaccination</article-title><alt-title alt-title-type="running-head">Antibody Profile Measured by Microarray</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Huijskens</surname><given-names>Elisabeth G. W.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Reimerink</surname><given-names>Johan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mulder</surname><given-names>Paul G. H.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>van Beek</surname><given-names>Janko</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Meijer</surname><given-names>Adam</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>de Bruin</surname><given-names>Erwin</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Friesema</surname><given-names>Ingrid</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>de Jong</surname><given-names>Menno D.</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rimmelzwaan</surname><given-names>Guus F.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" deceased="yes"><name><surname>Peeters</surname><given-names>Marcel F.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rossen</surname><given-names>John W. A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Koopmans</surname><given-names>Marion</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Laboratory of Medical Microbiology and Immunology, St. Elisabeth Hospital, Tilburg, The Netherlands</addr-line></aff><aff id="aff2"><label>2</label><addr-line>National Institute of Public Health and the Environment, RIVM, Bilthoven, The Netherlands</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Amphia Academy, Amphia Hospital, Breda, The Netherlands</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands</addr-line></aff><aff id="aff6"><label>6</label><addr-line>Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Renukaradhya</surname><given-names>Gourapura J.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"></xref></contrib></contrib-group><aff id="edit1"><addr-line>The Ohio State University, United States of America</addr-line></aff><author-notes><corresp id="cor1">* E-mail: <email>i.huijskens@gmail.com</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: EH J. Reimerink JVB EDB MP J. Rossen MK. Performed the experiments: EH J. Reimerink JVB EDB MK. Analyzed the data: EH J. Reimerink PM JVB MDJ GR J. Rossen MK. Contributed reagents/materials/analysis tools: AM IF MDJ GR. Wrote the paper: EH PM MK.</p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>24</day><month>1</month><year>2013</year></pub-date><volume>8</volume><issue>1</issue><elocation-id>e54890</elocation-id><history><date date-type="received"><day>11</day><month>7</month><year>2012</year></date><date date-type="accepted"><day>18</day><month>12</month><year>2012</year></date></history><permissions><copyright-statement>© 2013 Huijskens et al</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Huijskens et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>The influence of prior seasonal influenza vaccination on the antibody response produced by natural infection or vaccination is not well understood.</p></sec><sec><title>Methods</title><p>We compared the profiles of antibody responses of 32 naturally infected subjects and 98 subjects vaccinated with a 2009 influenza A(H1N1) monovalent MF59-adjuvanted vaccine (Focetria®, Novartis), with and without a history of seasonal influenza vaccination. Antibodies were measured by hemagglutination inhibition (HI) assay for influenza A(H1N1)pdm09 and by protein microarray (PA) using the HA1 subunit for seven recent and historic H1, H2 and H3 influenza viruses, and three avian influenza viruses. Serum samples for the infection group were taken at the moment of collection of the diagnostic sample, 10 days and 30 days after onset of influenza symptoms. For the vaccination group, samples were drawn at baseline, 3 weeks after the first vaccination and 5 weeks after the second vaccination.</p></sec><sec><title>Results</title><p>We showed that subjects with a history of seasonal vaccination generally exhibited higher baseline titers for the various HA1 antigens than subjects without a seasonal vaccination history. Infection and pandemic influenza vaccination responses in persons with a history of seasonal vaccination were skewed towards historic antigens.</p></sec><sec><title>Conclusions</title><p>Seasonal vaccination is of significant influence on the antibody response to subsequent infection and vaccination, and further research is needed to understand the effect of annual vaccination on protective immunity.</p></sec></abstract><funding-group><funding-statement>The authors have no support or funding to report.</funding-statement></funding-group><counts><page-count count="7"></page-count></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>The first influenza pandemic of the 21st century was caused by a novel influenza A(H1N1) virus, which was a complex reassortant virus containing genes from avian, human, and swine influenza viruses. <xref rid="pone.0054890-WHO1" ref-type="bibr">[1]</xref> Hemagglutinin (HA) rapidly and continuously accumulates mutations to escape recognition by virus-specific antibodies. To date, epidemics and pandemics of influenza in humans have been restricted to viruses with subtype H1, H2, and H3 surface HAs, combined with neuraminidase proteins (NA) of subtypes N1 and N2. However, sporadic zoonotic infections with avian influenza viruses of subtypes H5, H7 and H9 have been documented. <xref rid="pone.0054890-Jia1" ref-type="bibr">[2]</xref> The potential diversity of influenza viruses is larger, as sixteen subtypes of HA and 9 subtypes of NA have been identified in wild waterfowl, that constitute a reservoir for influenza viruses. <xref rid="pone.0054890-Russell1" ref-type="bibr">[3]</xref> The occasional zoonotic transmissions, and the opportunity for human adaptation of animal influenza viruses through reassortment or adaptation, constitute a continuous pandemic threat, as illustrated by the recent pandemic in 2009. Impact of such a new introduction is determined in part by the level of pre-existing immunity in the population. Natural influenza virus infection elicits a protective immune response, mediated primarily through neutralizing antibodies directed to host-cell binding domains on the surface proteins of the infecting strain and antigenically related viruses. An important question related to the emergence of new influenza viruses, however, is the degree of antigenic mismatch that can be tolerated before virus-neutralising antibodies are no longer capable of inhibiting infection. Also, the role of antibodies to other epitopes is poorly understood. Recently, human monoclonal antibodies against highly conserved influenza virus epitopes in the stalk region were discovered with broad neutralizing activity against a wide spectrum of influenza subtypes. <xref rid="pone.0054890-Friesen1" ref-type="bibr">[4]</xref>, <xref rid="pone.0054890-Ekiert1" ref-type="bibr">[5]</xref> Similarly, low level cross-reactive antibodies that bind to the globular head (HA1) have been found in some individuals (Baas et al., submitted for publication). An important question is whether the presence of such broad non-neutralising antibodies may somehow influence infection. During the recent pandemic, this discussion was further triggered because of the observed discrepancy between the population immunity estimates based on serology and the observed impact: cross-neutralizing antibodies were found in persons exposed to historic influenza A(H1N1) strains that were circulating prior to the emergence of the pandemic influenza H2N2 strain in 1956/57. <xref rid="pone.0054890-Hancock1" ref-type="bibr">[6]</xref> Nevertheless, only a small fraction of persons older than 20 years of age were infected during the first pandemic wave, suggesting other factors influencing population susceptibility. <xref rid="pone.0054890-Steens1" ref-type="bibr">[7]</xref> Wrammert et al. <xref rid="pone.0054890-Wrammert1" ref-type="bibr">[8]</xref> identified broadly cross-reactive neutralizing antibodies induced by infection between the influenza A(H1N1)pdm09, recent seasonal influenza A(H1N1) strains, as well as influenza A(H1N1)1918, and avian influenza viruses of subtypes H5N1. Others showed that seasonal vaccination can induce heterosubtypic neutralizing antibodies as well. <xref rid="pone.0054890-Corti1" ref-type="bibr">[9]</xref>, <xref rid="pone.0054890-Ding1" ref-type="bibr">[10]</xref> Somewhat contrasting with this is the observation that a history of seasonal vaccination can lead to lower levels and shorter duration of the strain-specific antibody responses upon heterologous infection. <xref rid="pone.0054890-Bodewes1" ref-type="bibr">[11]</xref>, <xref rid="pone.0054890-Huijskens1" ref-type="bibr">[12]</xref>.</p><p>These findings show that the exposure history of individuals needs to be considered in order to better understand the role of antibodies in susceptibility to infection,. A commonly used measure for determination of protective antibodies induced by influenza virus infection and vaccination is the hemagglutination inhibition (HI) assay, where a HI titer ≥40 has been associated with 50% protection against influenza virus infection in susceptible populations. <xref rid="pone.0054890-deJong1" ref-type="bibr">[13]</xref> HI assays, however, lack reproducibility between laboratories, for example due to inter-observer variability in visual read-outs of the agglutination titer and the nature and quality of the erythrocytes that are used in the assay. In addition, a practical limitation is the need for high amounts of virus and serum when antibodies to multiple strains need to be determined, and a biosafety level II and III working environment. <xref rid="pone.0054890-deJong1" ref-type="bibr">[13]</xref>, <xref rid="pone.0054890-Alvarez1" ref-type="bibr">[14]</xref> Testing for antibodies by micro-neutralization assay has similar disadvantages, and is not widely available, thereby limiting their use for comparative studies. ELISA assays have suffered from lack of specificity, due to broad cross reactivity when HA antigens are used. Therefore, we explored alternatives for HI antibody testing, and developed a protein microarray based assay to measure antibodies to the HA1 subunit from a wide range of viruses, including seven recent and historic seasonal H1, H2 and H3 influenza viruses, the A(H1N1)pdm09 influenza virus, and three avian influenza viruses. <xref rid="pone.0054890-Koopmans1" ref-type="bibr">[15]</xref> Use of this assay revealed substantial diversity in the antibody profile of individuals, depending on age, but also on exposure history and on individual host responses. In this study, we compared the profile of antibody responses elicited by natural infection, and vaccination for influenza A(H1N1)pdm09 in healthy adults with and without a history of seasonal influenza vaccination using the protein microarray.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Ethics Statement</title><p>Both studies were approved by the appropriate institutional review boards; the Medical Ethical Review Committee of the St. Elisabeth Hospital, Tilburg, The Netherlands and the Medical Ethical Review Committee of the University Medical Centre, Utrecht. Written informed consent was obtained from the participant or parents/guardians in case of the children.</p></sec><sec id="s2b"><title>Subjects</title><sec id="s2b1"><title>Vaccination group</title><p>We conducted a prospective, longitudinal study from November 2009 through June 2010 at the St. Elisabeth and TweeSteden Hospital, Tilburg, The Netherlands. <xref rid="pone.0054890-Huijskens1" ref-type="bibr">[12]</xref> Healthcare workers (≥18 years; if pregnant only after 13 weeks of pregnancy) of both hospitals were eligible for inclusion. Serum samples were collected prior to the first vaccination with a 2009 influenza A(H1N1) monovalent MF59-adjuvanted vaccine (Focetria®, Novartis), before the second vaccination (three weeks later) and before the vaccination with trivalent seasonal influenza vaccine (5 weeks after the second vaccination). Demographic characteristics (age and sex), seasonal influenza vaccination status, and comorbidity were collected by means of a short questionnaire. Two subgroups were made: a group that never received seasonal vaccination and a group that received seasonal influenza vaccination annually.</p></sec><sec id="s2b2"><title>Infection group</title><p>We used serum samples from a national pandemic influenza cohort study. <xref rid="pone.0054890-Friesema1" ref-type="bibr">[16]</xref> Patients and some of their household contacts had been diagnosed with influenza during the active case finding activities instituted in the early phase of the pandemic. Persons testing positive for influenza A(H1N1)pdm09 by RT-PCR testing of a throat/nose swab were contacted and asked if they were willing to participate in a national cohort study. We obtained three samples; the first sample taken between 0 - 5 days after onset of influenza symptoms, the 2nd at 10 days after onset, and the third sample at around 30 days. We used data on age, sex, date of onset of illness, and seasonal influenza vaccination status. Two subgroups were made: a group not receiving regular vaccination and a group that was regularly vaccinated.</p></sec></sec><sec id="s2c"><title>Antibody-titer Determination by Hemagglutination Inhibition Assay (HI)</title><p>Virus specific antibodies were measured by HI assay, using egg-grown A/California/7/2009 A(H1N1) pandemic virus, and fresh red blood cells of turkeys in Alsever’s solution (Biotrading, The Netherlands), according to standard methods. <xref rid="pone.0054890-Huijskens1" ref-type="bibr">[12]</xref> The HI titer was the reciprocal of the highest dilution of serum that inhibited virus induced hemagglutination. Titers below the detection limit of 10 were assigned to a value of 5, and 1280 was the end point titration and also the highest dilution tested. Titers were calibrated against a candidate International Standard for antibody-titers to influenza A(H1N1)pdm09 virus. <xref rid="pone.0054890-NIBSC1" ref-type="bibr">[17]</xref>.</p></sec><sec id="s2d"><title>Antibody Determination by Protein Array (PA)</title><p>Antibody titers were determined by PA as previously described. <xref rid="pone.0054890-Koopmans1" ref-type="bibr">[15]</xref> Briefly serum samples were tested in 2 fold serial dilutions from 1∶20 to 1∶2560 on nitrocellulose slides pre-coated with a selection of recombinant monomeric HA1 proteins (<xref ref-type="table" rid="pone-0054890-t001"><bold>Table 1</bold></xref>). Inter-assay variability was monitored by testing dilutions of a candidate International Standard for antibody-titers to influenza A(H1N1)pdm09 virus. <xref rid="pone.0054890-NIBSC1" ref-type="bibr">[17]</xref> Trays with a H1 titer for the International Standard deviating more than one titer step from the GMT of all standards in the particular run were rejected. Microarray slides were scanned using a ScanArray Gx Plus microarray scanner (PerkinElmer) and median spot fluorescence intensity was determined by using ScanArray Express (version 4.0) software (PerkinElmer). Titers were calculated from the inflection point of the titration curve as described. <xref rid="pone.0054890-Koopmans1" ref-type="bibr">[15]</xref> Specificity of reactivity was determined using subtype-specific rabbit antisera, sera from persons of different age-groups with exposure to different seasonal influenza viruses, and supernatants from cloned human memory B cells. Full details of the array validation have been published elsewhere.( <xref rid="pone.0054890-Koopmans1" ref-type="bibr">[15]</xref>, Baas et al., submitted).</p><table-wrap id="pone-0054890-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0054890.t001</object-id><label>Table 1</label><caption><title>HA1 antigens used for the microarray.</title></caption><alternatives><graphic id="pone-0054890-t001-1" xlink:href="pone.0054890.t001"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Name</td><td align="left" rowspan="1" colspan="1">Strain</td><td align="left" rowspan="1" colspan="1">Subtype</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">H1-1999</td><td align="left" rowspan="1" colspan="1">A/New Caledonia/20/99</td><td align="left" rowspan="1" colspan="1">H1N1</td></tr><tr><td align="left" rowspan="1" colspan="1">H1-2007</td><td align="left" rowspan="1" colspan="1">A/Brisbane/59/2007</td><td align="left" rowspan="1" colspan="1">H1N1</td></tr><tr><td align="left" rowspan="1" colspan="1">H1-1933</td><td align="left" rowspan="1" colspan="1">A/WS/33</td><td align="left" rowspan="1" colspan="1">H1N1</td></tr><tr><td align="left" rowspan="1" colspan="1">H1-2009</td><td align="left" rowspan="1" colspan="1">A/California/6/2009</td><td align="left" rowspan="1" colspan="1">H1N1</td></tr><tr><td align="left" rowspan="1" colspan="1">H1-1918</td><td align="left" rowspan="1" colspan="1">A/South Caroline/1/18</td><td align="left" rowspan="1" colspan="1">H1N1</td></tr><tr><td align="left" rowspan="1" colspan="1">H2-1957</td><td align="left" rowspan="1" colspan="1">A/Canada/720/05</td><td align="left" rowspan="1" colspan="1">H2N2</td></tr><tr><td align="left" rowspan="1" colspan="1">H3-2003</td><td align="left" rowspan="1" colspan="1">A/Wyoming/3/03</td><td align="left" rowspan="1" colspan="1">H3N2</td></tr><tr><td align="left" rowspan="1" colspan="1">H3-2007</td><td align="left" rowspan="1" colspan="1">A/Brisbane/10/2007</td><td align="left" rowspan="1" colspan="1">H3N2</td></tr><tr><td align="left" rowspan="1" colspan="1">H5-2004</td><td align="left" rowspan="1" colspan="1">A/Vietnam/1194/2004</td><td align="left" rowspan="1" colspan="1">H5N1</td></tr><tr><td align="left" rowspan="1" colspan="1">H7-2003</td><td align="left" rowspan="1" colspan="1">A/Chicken/Netherlands/1/03</td><td align="left" rowspan="1" colspan="1">H7N7</td></tr><tr><td align="left" rowspan="1" colspan="1">H9-1999</td><td align="left" rowspan="1" colspan="1">A/Guinea fowl/Hong Kong/WF10/99</td><td align="left" rowspan="1" colspan="1">H9N2</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="s2e"><title>Statistical Analyses</title><p>Differences in age and gender between the vaccination and infection group were tested using the Mann-Whitney and chi-square test, respectively. Antibody levels were analyzed for both groups against timing of sampling, age, gender, and vaccination history, using linear mixed modeling after log-transformation. Separate analyses were performed in the vaccination and infection group. Also the interaction between time (three time points) and seasonal vaccination (yes/no) was entered in the model if significant. No structure was imposed on the residual (co)variances of the three repeated titer measurements. Estimated coefficients and their 95% confidence limits were back-transformed to be interpretable as geometric mean titers (GMT) and multiplicative change factors between those GMTs.</p><p>A titer rise was defined as a 4-fold or greater increase in antibody titer between the first sample (with a minimum titer of 40 for PA) and follow-up samples from the same individual. Seroconversion was defined as an increase from below to above a titer of 40.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Comparison of Vaccination- and Natural Infection-group</title><p>A total of 130 subjects were included, with 98 persons in the vaccination group and 32 in the natural infection-group. Details of the study groups are shown in <xref ref-type="table" rid="pone-0054890-t002"><bold>Table 2</bold></xref>. The median age of the vaccination group was 49 years (range, 25 to 66), 35 (35.7%) were men; 40 subjects (40.8%) had received annual seasonal influenza vaccination. The naturally infected patients were younger (p<0.0005) and were more often male (p 0.040) than in the vaccination group: the median age was 30 years (range, 12 to 66), 18 (56.3%) were men; 15 subjects (46.9%) had regularly been vaccinated against seasonal influenza virus.</p><table-wrap id="pone-0054890-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0054890.t002</object-id><label>Table 2</label><caption><title>Demographic characteristics of the subjects.</title></caption><alternatives><graphic id="pone-0054890-t002-2" xlink:href="pone.0054890.t002"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Characteristics</td><td align="left" rowspan="1" colspan="1">All subjects</td><td align="left" rowspan="1" colspan="1">Not yearly vaccinatedwith seasonal vaccine</td><td align="left" rowspan="1" colspan="1">Yearly vaccinated with seasonalvaccine</td><td align="left" rowspan="1" colspan="1">Natural infection withH1N1(2009) without earlierseasonal vaccine</td><td align="left" rowspan="1" colspan="1">Natural infection withH1N1(2009) with earlierseasonal vaccine</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"><italic>n = 130</italic></td><td align="left" rowspan="1" colspan="1"><italic>n = 58</italic></td><td align="left" rowspan="1" colspan="1"><italic>n = 40</italic></td><td align="left" rowspan="1" colspan="1"><italic>n = 17</italic></td><td align="left" rowspan="1" colspan="1"><italic>n = 15</italic></td></tr></thead><tbody><tr><td colspan="6" align="left" rowspan="1"><bold>Age - yrs.</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Median</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">51</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">29</td></tr><tr><td align="left" rowspan="1" colspan="1">Range</td><td align="left" rowspan="1" colspan="1">12–66</td><td align="left" rowspan="1" colspan="1">28–61</td><td align="left" rowspan="1" colspan="1">25–66</td><td align="left" rowspan="1" colspan="1">14–60</td><td align="left" rowspan="1" colspan="1">12–66</td></tr><tr><td colspan="6" align="left" rowspan="1"><bold>Sex – no. (%)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">53 (40.8)</td><td align="left" rowspan="1" colspan="1">20 (34.5)</td><td align="left" rowspan="1" colspan="1">15 (37.5)</td><td align="left" rowspan="1" colspan="1">10 (58.8)</td><td align="left" rowspan="1" colspan="1">8 (53.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">77 (59.2)</td><td align="left" rowspan="1" colspan="1">38 (65.5)</td><td align="left" rowspan="1" colspan="1">25 (62.5)</td><td align="left" rowspan="1" colspan="1">7 (41.2)</td><td align="left" rowspan="1" colspan="1">7 (46.7)</td></tr><tr><td colspan="6" align="left" rowspan="1"><bold>Vaccinated since (%)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Before 2000</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">15 (37.5)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Nk<xref ref-type="table-fn" rid="nt101">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">2000–2004</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">20 (50.0)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Nk<xref ref-type="table-fn" rid="nt101">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">After 2004</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">5 (12.5)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Nk<xref ref-type="table-fn" rid="nt101">*</xref></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label>*</label><p>Not known.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Kinetics of Antibody Response to Influenza A(H1N1)pdm09</title><p>Trends in GMTs at baseline and at the different time points are shown for both groups in <xref ref-type="fig" rid="pone-0054890-g001"><bold>Figure 1</bold></xref>. Seventy-two of the 98 vaccinees and 22 of the 32 infected patients showed a titer increase or seroconversion for the homologous antigen as measured by PA, and 91 of the 98 vaccinees and 27 of the 32 infected patients as measured by HI.</p><fig id="pone-0054890-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0054890.g001</object-id><label>Figure 1</label><caption><title>HI versus PA for influenza A(H1N1)pdm09 in the natural infection-group and in the vaccination group. A.</title><p>GMTs of influenza A(H1N1)pdm09 for HI versus PA in the natural infection-group, with and without prior seasonal vaccination at time point 0 represents baseline, time point 1 represents 10 days after day of onset of influenza symptoms and time point 2 represents 30 days after day of onset of influenza symptoms. <bold>B.</bold> GMTs of influenza A(H1N1)pdm09 for HI versus PA in the vaccination group, with and without prior seasonal influenza vaccination at time point 0 represents baseline, time point 1 represents 3 weeks after the first vaccination and before the second vaccination and time point 2 represents 5 weeks after the second vaccination. Y axis denotes average GMT (adjusted for gender and age).</p></caption><graphic xlink:href="pone.0054890.g001"></graphic></fig><p>When comparing titers against the homologous antigen A(H1N1)pdm09, GMTs measured by PA were higher than those measured by HI at all time points in both groups, with no obvious differences between vaccinees and patients. However, when stratifying the data according to seasonal vaccination history, a difference in antibody responses was observed between both groups. Naturally infected persons with a history of seasonal vaccination showed a stronger antibody response to A(H1N1)pdm09 by both HI and PA than persons without a history of seasonal vaccination. This contrasted with opposite results in persons who received the pandemic vaccine: vaccinees with a history of seasonal influenza vaccination showed a less pronounced response by both methods than persons who were never vaccinated. Similar to observations for the whole groups, the magnitude of responses measured by the two techniques also differed, with highest GMTs measured by PA. The antibody responses measured by both methods were co-linear, except for the naturally infected persons with a history of vaccination: here, the curve for the response measured by PA was steeper, suggesting a disproportionate increase in non-HI antibodies in this group.</p></sec><sec id="s3c"><title>Antibody Expression Profiles</title><p>To gain a more detailed understanding of the quality and composition of the antibody response, we profiled sera against 7 antigens using the PA. The expression profile of the different antigens in response to natural infection and vaccination against influenza A(H1N1)pdm09 was analyzed using linear mixed modeling, with adjustments made for gender and age. A ratio was calculated to indicate the increment between groups with and without seasonal vaccination.</p><sec id="s3c1"><title>Antibody profile in response to influenza A(H1N1)pdm09 virus infection with and without seasonal influenza vaccination</title><p>When comparing change in titer compared to baseline in the natural infection-group, the greatest increase (fold change) was observed for the homologous antigen, followed by 1918 and the other H1 antigens. Smaller but significant rises in antibody titer were observed for all other antigens except H5-2004. Subjects with a history of seasonal influenza virus vaccination showed a significantly higher baseline titer for the historic and recent H1 and H3 influenza antigens, but not for H2 and the avian influenza virus antigens (<xref ref-type="fig" rid="pone-0054890-g002"><bold>Figure 2</bold></xref>). The natural infection-group had a greater increase in titer for all antigens than the vaccination group, although the response in the persons with seasonal vaccination history was skewed towards seasonal influenza antigens H1-1999 and H1-2007, for which most significant differences in response were observed. No significant interaction between time and former seasonal vaccination was found for any of the antigens in this infection group, adjusted for age and gender. Absence of this above mentioned interaction coincides with a model where the time courses of the titers in both vaccination history subgroups are parallel. (Described in <xref ref-type="supplementary-material" rid="pone.0054890.s001">Table S1</xref>).</p><fig id="pone-0054890-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0054890.g002</object-id><label>Figure 2</label><caption><title>Geometric mean titers (GMT) at time point 1 and 2 of the natural infection-group and in the vaccination group with and without former seasonal influenza vaccination. A.</title><p>GMTs for the various influenza HA1 antigens in patients infected with pandemic influenza H1 2009, with and without a history of seasonal vaccination at time point 1 (10 days after day of onset of influenza symptoms) and time point 2 (30 days after day of onset of influenza symptoms). <bold>B.</bold> GMTs for the various influenza HA1 antigens in subjects vaccinated with inactivated MF-59 adjuvated pandemic Influenza A virus (H1N1) 2009, with and without a history of seasonal influenza vaccination at time point 0, 1 (3 weeks after the first vaccination and before the second vaccination) and time point 2 (5 weeks after the second vaccination). Y axis denotes average GMT (adjusted for gender and age).</p></caption><graphic xlink:href="pone.0054890.g002"></graphic></fig></sec><sec id="s3c2"><title>Antibody profile in response to vaccination against influenza A(H1N1)pdm09 with and without seasonal influenza vaccination</title><p>In persons without a history of seasonal vaccination, the magnitude of the antibody response (fold change) was highest for the homologous and the H1-1918 antigens. Smaller rises in antibody titers were observed for all other seasonal H1 viruses and to a lesser extent for H2 and H3. In persons with a history of annual seasonal vaccination, the GMT at baseline was higher than those without previous vaccination, but the magnitude of response was much lower, and narrower, with seroconversion or significant increase in titer largely limited to the H1-2009 antigen. In persons without a history of seasonal vaccination, peak responses were measured already at the time of the booster vaccination with the pandemic vaccine, whereas this was not the case for persons with a history of seasonal influenza vaccination: here, the maximum change in titer was lower, and continued to increase until the third time point of sampling, after the second vaccine dose was given as seen in <xref ref-type="fig" rid="pone-0054890-g002"><bold>Figure 2</bold></xref>. (Further described in <xref ref-type="supplementary-material" rid="pone.0054890.s002">Table S2</xref>).</p></sec></sec></sec><sec id="s4"><title>Discussion</title><p>In the present study, we compared antibody profiles in response to infection and vaccination with influenza A(H1N1)pdm09 with a PA. This technology was developed to enable comparative studies using standardized assay format to reduce the problem of variability and potentially interlaboratory differences in results of HI and microneutralization testing by obviating the need for use of biological reagents that are difficult to standardize, such as red blood cells (for HI assays) or cells (for virus neutralization assays). <xref rid="pone.0054890-Koopmans1" ref-type="bibr">[15]</xref> We demonstrated that subjects with a history of seasonal vaccination generally exhibited higher baseline titers for the various HA antigens than subjects without such history. We also show that the response differs according to the type of exposure: following natural infection, a strong homologous response, and weaker but significant increases in antibody titers to different HA1 antigens are seen, whereas the response following vaccination was more restricted. These results need to be interpreted with caution, because the mean age of the persons in the infection group was lower, which in part could explain a more vigorous antibody response. Remarkably, in both groups, responses in persons with a history of vaccination were skewed towards older seasonal H1 antigens. These details were not evident from the kinetics in HI titer, the method routinely used for evaluation of antibody responses.</p><p>The study confirms that antibody response to infection and vaccination are both shaped by prior exposure history, where prior regular seasonal influenza virus vaccination had a clear effect on the magnitude and kinetics of response to pandemic influenza infection and vaccination. The higher GMTs at baseline were particularly clear for antibodies binding to HA1 peptide from recent seasonal influenza viruses, but slightly elevated levels were also observed for antigens not offered through vaccination within subtype H1. These reactivities may reflect the broadening of antibody response with age. <xref rid="pone.0054890-Koopmans1" ref-type="bibr">[15]</xref> An intriguing question is whether such antibodies influence outcome of infection. Studies during the pandemic have been inconclusive in this respect: The presence of cross-neutralizing antibodies was limited to higher age groups, and no protective effect was expected or observed in several studies. <xref rid="pone.0054890-Hancock1" ref-type="bibr">[6]</xref>, <xref rid="pone.0054890-Jefferies1" ref-type="bibr">[18]</xref>, <xref rid="pone.0054890-Kelly1" ref-type="bibr">[19]</xref> In contrast with this, some degree of cross protection from severe illness by prior seasonal vaccination was suggested in some studies. <xref rid="pone.0054890-Couch1" ref-type="bibr">[20]</xref>, <xref rid="pone.0054890-GarciaGarcia1" ref-type="bibr">[21]</xref>, <xref rid="pone.0054890-Johns1" ref-type="bibr">[22]</xref> Prior infection with an influenza A virus can reduce morbidity and mortality caused by an infection with an antigenically divergent influenza A virus because of heterosubtypic immunity, both within and between subtypes. <xref rid="pone.0054890-Grebe1" ref-type="bibr">[23]</xref> Both natural infection and seasonal vaccination can induce heterosubtypic neutralizing antibodies, but our data suggest skewing against such antibodies in persons with a history of seasonal vaccination. <xref rid="pone.0054890-Wrammert1" ref-type="bibr">[8]</xref>, <xref rid="pone.0054890-Corti1" ref-type="bibr">[9]</xref>, <xref rid="pone.0054890-Ding1" ref-type="bibr">[10]</xref> The immunological basis of heterosubtypic immunity is not fully understood, but B cells, CD4<sup>+</sup> and CD8<sup>+</sup> T-cells and mucosal immunity may contribute. <xref rid="pone.0054890-Bodewes1" ref-type="bibr">[11]</xref>, <xref rid="pone.0054890-Grebe1" ref-type="bibr">[23]</xref> Passive serum transfer showed that antibodies induced by seasonal influenza A(H1N1) virus conferred protection in naïve recipient mice against A(H1N1)pdm09 challenge. The presence or absence of HI antibodies, therefore, is not the sole indicator of the effectiveness of protective cross-reactive antibody immunity. <xref rid="pone.0054890-Fang1" ref-type="bibr">[24]</xref> In a mouse model, Hillaire et al. <xref rid="pone.0054890-Hillaire1" ref-type="bibr">[25]</xref>, demonstrated that induction of T cells specific for a seasonal H3N2 influenza virus led to protection against infection with the antigenically unrelated A(H1N1)pdm09. In addition, repeated infection with seasonal influenza virus improved protection and clearance of influenza A(H1N1)pdm09 in ferrets. <xref rid="pone.0054890-Laurie1" ref-type="bibr">[26]</xref> In young children, a difference was observed in levels of CD8+ T cells between vaccinated and unvaccinated individuals, suggesting that the same mechanisms may apply in humans as postulated by Bodewes et al. <xref rid="pone.0054890-Bodewes2" ref-type="bibr">[27]</xref>, <xref rid="pone.0054890-Bodewes3" ref-type="bibr">[28]</xref> The influenza pandemic of 2009 showed an unbalanced age distribution of infected individuals, with a low incidence in elderly and a high incidence in children. This could be partly explained by the lack of heterosubtypic immunity, as a proportion of young children are immunologically naïve for influenza viruses. <xref rid="pone.0054890-Hancock1" ref-type="bibr">[6]</xref>, <xref rid="pone.0054890-Bodewes4" ref-type="bibr">[29]</xref> However, others described that low level heterosubtypic antibody responses following seasonal influenza vaccination could offer immune protection against antigenically distinct influenza viruses to a certain extent. <xref rid="pone.0054890-Corti1" ref-type="bibr">[9]</xref>, <xref rid="pone.0054890-Ding1" ref-type="bibr">[10]</xref>, <xref rid="pone.0054890-Gioia1" ref-type="bibr">[30]</xref> The observations above imply that seasonal influenza vaccines should also be evaluated for their capacity to mimic the balance in response triggered by wild type infection. Studies from Skowronski et al. <xref rid="pone.0054890-Skowronski1" ref-type="bibr">[31]</xref>, <xref rid="pone.0054890-Skowronski2" ref-type="bibr">[32]</xref> suggested an increased risk of illness in persons with a history of seasonal influenza vaccination during the pandemic, which potentially could be explained by reduced levels of cross protective antibodies or T cells as a result of reduced wild type infection.</p><sec id="s4a"><title>Conclusions</title><p>In this study, we show that a history of seasonal influenza vaccination has different effects on infection and vaccination response. In vaccinees, the level of antibodies to the homologous strain was reduced in persons with a history of vaccination, whereas the reverse was true for infected persons. In both groups, however, the antibody response was skewed against heterologous antigens. More research is needed to understand if these observations are relevant for susceptibility of the individuals for infection and disease. We also conclude that improved assessment of the quality of immune response is needed when evaluation current and potential influenza vaccines.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0054890.s001"><label>Table S1</label><caption><p><bold>Geometric mean titers (GMT) at baseline and after natural infection with pandemic influenza H1 2009.</bold> GMT estimates are expressed as fold change for GMTs in persons with and without a history of seasonal vaccination (GMTvaccinated/GMTnonvaccinated).</p><p>(DOC)</p></caption><media xlink:href="pone.0054890.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0054890.s002"><label>Table S2</label><caption><p><bold>Geometric mean titers (GMT) at baseline and after vaccination with pandemic H1 2009 vaccine of persons with and without a history of seasonal vaccination.</bold></p><p>(DOC)</p></caption><media xlink:href="pone.0054890.s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank the healthcare workers and patients for their critical role in this study and Jeanine van Erkel for technical assistance. We especially want to honor Dr. MF Peeters, senior investigator and mentor, who passed away during this study.</p></ack><ref-list><title>References</title><ref id="pone.0054890-WHO1"><label>1</label><mixed-citation publication-type="other">WHO (2011) Available: <ext-link ext-link-type="uri" xlink:href="http://www.euro.who.int/influenza/ah1n1">http://www.euro.who.int/influenza/ah1n1</ext-link>.Accessed 2012 Jun 28.</mixed-citation></ref><ref id="pone.0054890-Jia1"><label>2</label><mixed-citation publication-type="journal"><name><surname>Jia</surname><given-names>N</given-names></name>, <name><surname>de Vlas</surname><given-names>SJ</given-names></name>, <name><surname>Liu</surname><given-names>YX</given-names></name>, <name><surname>Zhang</surname><given-names>JS</given-names></name>, <name><surname>Zhan</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Serological reports of human infections of H7 and H9 avian influenza viruses in northern China</article-title>. <source>J Clin Virol</source><volume>44</volume>: <fpage>225</fpage>–<lpage>229</lpage>.<pub-id pub-id-type="pmid">19186101</pub-id></mixed-citation></ref><ref id="pone.0054890-Russell1"><label>3</label><mixed-citation publication-type="journal"><name><surname>Russell</surname><given-names>RJ</given-names></name>, <name><surname>Burns</surname><given-names>WH</given-names></name>, <name><surname>White</surname><given-names>DO</given-names></name>, <name><surname>Anders</surname><given-names>EM</given-names></name>, <name><surname>Ward</surname><given-names>CW</given-names></name>, <etal>et al</etal> (<year>1979</year>) <article-title>Antigenic determinants of influenza virus hemagglutinin. III. Competitive binding of antibodies directed against “common” and “strain-specific” antigenic determinants of A/Memphis/72 hemagglutinin</article-title>. <source>J Immunol</source><volume>123</volume>: <fpage>825</fpage>–<lpage>832</lpage>.<pub-id pub-id-type="pmid">88484</pub-id></mixed-citation></ref><ref id="pone.0054890-Friesen1"><label>4</label><mixed-citation publication-type="journal"><name><surname>Friesen</surname><given-names>RH</given-names></name>, <name><surname>Koudstaal</surname><given-names>W</given-names></name>, <name><surname>Koldijk</surname><given-names>MH</given-names></name>, <name><surname>Weverling</surname><given-names>GJ</given-names></name>, <name><surname>Brakenhoff</surname><given-names>JP</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets</article-title>. <source>PLoS One</source><volume>5</volume>: <fpage>e9106</fpage>.<pub-id pub-id-type="pmid">20161706</pub-id></mixed-citation></ref><ref id="pone.0054890-Ekiert1"><label>5</label><mixed-citation publication-type="journal"><name><surname>Ekiert</surname><given-names>DC</given-names></name>, <name><surname>Bhabha</surname><given-names>G</given-names></name>, <name><surname>Elsliger</surname><given-names>MA</given-names></name>, <name><surname>Friesen</surname><given-names>RH</given-names></name>, <name><surname>Jongeneelen</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Antibody recognition of a highly conserved influenza virus epitope</article-title>. <source>Science</source><volume>324</volume>: <fpage>246</fpage>–<lpage>251</lpage>.<pub-id pub-id-type="pmid">19251591</pub-id></mixed-citation></ref><ref id="pone.0054890-Hancock1"><label>6</label><mixed-citation publication-type="journal"><name><surname>Hancock</surname><given-names>K</given-names></name>, <name><surname>Veguilla</surname><given-names>V</given-names></name>, <name><surname>Lu</surname><given-names>X</given-names></name>, <name><surname>Zhong</surname><given-names>W</given-names></name>, <name><surname>Butler</surname><given-names>EN</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus</article-title>. <source>N Engl J Med</source><volume>361</volume>: <fpage>1945</fpage>–<lpage>1952</lpage>.<pub-id pub-id-type="pmid">19745214</pub-id></mixed-citation></ref><ref id="pone.0054890-Steens1"><label>7</label><mixed-citation publication-type="journal"><name><surname>Steens</surname><given-names>A</given-names></name>, <name><surname>Waaijenborg</surname><given-names>S</given-names></name>, <name><surname>Teunis</surname><given-names>PF</given-names></name>, <name><surname>Reimerink</surname><given-names>JH</given-names></name>, <name><surname>Meijer</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Age-Dependent Patterns of Infection and Severity Explaining the Low Impact of 2009 Influenza A (H1N1): Evidence From Serial Serologic Surveys in the Netherlands</article-title>. <source>Am J Epidemiol</source><volume>174</volume>: <fpage>1307</fpage>–<lpage>1315</lpage>.<pub-id pub-id-type="pmid">22025354</pub-id></mixed-citation></ref><ref id="pone.0054890-Wrammert1"><label>8</label><mixed-citation publication-type="journal"><name><surname>Wrammert</surname><given-names>J</given-names></name>, <name><surname>Koutsonanos</surname><given-names>D</given-names></name>, <name><surname>Li</surname><given-names>GM</given-names></name>, <name><surname>Edupuganti</surname><given-names>S</given-names></name>, <name><surname>Sui</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection</article-title>. <source>J Exp Med</source><volume>208</volume>: <fpage>181</fpage>–<lpage>193</lpage>.<pub-id pub-id-type="pmid">21220454</pub-id></mixed-citation></ref><ref id="pone.0054890-Corti1"><label>9</label><mixed-citation publication-type="journal"><name><surname>Corti</surname><given-names>D</given-names></name>, <name><surname>Suguitan</surname><given-names>AL</given-names><suffix>Jr</suffix></name>, <name><surname>Pinna</surname><given-names>D</given-names></name>, <name><surname>Silacci</surname><given-names>C</given-names></name>, <name><surname>Fernandez-Rodriguez</surname><given-names>BM</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine</article-title>. <source>J Clin Invest</source><volume>120</volume>: <fpage>1663</fpage>–<lpage>1673</lpage>.<pub-id pub-id-type="pmid">20389023</pub-id></mixed-citation></ref><ref id="pone.0054890-Ding1"><label>10</label><mixed-citation publication-type="journal"><name><surname>Ding</surname><given-names>H</given-names></name>, <name><surname>Tsai</surname><given-names>C</given-names></name>, <name><surname>Zhou</surname><given-names>F</given-names></name>, <name><surname>Buchy</surname><given-names>P</given-names></name>, <name><surname>Deubel</surname><given-names>V</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Heterosubtypic Antibody Response Elicited with Seasonal Influenza Vaccine Correlates Partial Protection against Highly Pathogenic H5N1 Virus</article-title>. <source>PLoS One</source><volume>6</volume>: <fpage>e17821</fpage>.<pub-id pub-id-type="pmid">21464977</pub-id></mixed-citation></ref><ref id="pone.0054890-Bodewes1"><label>11</label><mixed-citation publication-type="journal"><name><surname>Bodewes</surname><given-names>R</given-names></name>, <name><surname>Kreijtz</surname><given-names>JH</given-names></name>, <name><surname>Geelhoed-Mieras</surname><given-names>MM</given-names></name>, <name><surname>van Amerongen</surname><given-names>G</given-names></name>, <name><surname>Verburgh</surname><given-names>RJ</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets</article-title>. <source>J Virol</source><volume>85</volume>: <fpage>2695</fpage>–<lpage>2702</lpage>.<pub-id pub-id-type="pmid">21228239</pub-id></mixed-citation></ref><ref id="pone.0054890-Huijskens1"><label>12</label><mixed-citation publication-type="journal"><name><surname>Huijskens</surname><given-names>E</given-names></name>, <name><surname>Rossen</surname><given-names>J</given-names></name>, <name><surname>Mulder</surname><given-names>P</given-names></name>, <name><surname>van Beek</surname><given-names>R</given-names></name>, <name><surname>van Vugt</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population</article-title>. <source>Clin Vaccine Immunol</source><volume>18</volume>: <fpage>1401</fpage>–<lpage>1405</lpage>.<pub-id pub-id-type="pmid">21795459</pub-id></mixed-citation></ref><ref id="pone.0054890-deJong1"><label>13</label><mixed-citation publication-type="journal"><name><surname>de Jong</surname><given-names>JC</given-names></name>, <name><surname>Palache</surname><given-names>AM</given-names></name>, <name><surname>Beyer</surname><given-names>WE</given-names></name>, <name><surname>Rimmelzwaan</surname><given-names>GF</given-names></name>, <name><surname>Boon</surname><given-names>AC</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Haemagglutination-inhibiting antibody to influenza virus</article-title>. <source>Dev Biol (Basel)</source><volume>115</volume>: <fpage>63</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">15088777</pub-id></mixed-citation></ref><ref id="pone.0054890-Alvarez1"><label>14</label><mixed-citation publication-type="journal"><name><surname>Alvarez</surname><given-names>MM</given-names></name>, <name><surname>Lopez-Pacheco</surname><given-names>F</given-names></name>, <name><surname>Aguilar-Yanez</surname><given-names>JM</given-names></name>, <name><surname>Portillo-Lara</surname><given-names>R</given-names></name>, <name><surname>Mendoza-Ochoa</surname><given-names>GI</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Specific recognition of influenza A/H1N1/2009 antibodies in human serum: a simple virus-free ELISA method</article-title>. <source>PLoS One</source><volume>5</volume>: <fpage>e10176</fpage>.<pub-id pub-id-type="pmid">20418957</pub-id></mixed-citation></ref><ref id="pone.0054890-Koopmans1"><label>15</label><mixed-citation publication-type="journal"><name><surname>Koopmans</surname><given-names>M</given-names></name>, <name><surname>de Bruin</surname><given-names>E</given-names></name>, <name><surname>Godeke</surname><given-names>GJ</given-names></name>, <name><surname>Friesema</surname><given-names>I</given-names></name>, <name><surname>van Gageldonk</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Profiling of humoral immune responses to influenza viruses by using protein microarray</article-title>. <source>Clin Microbiol Infect</source><volume>18</volume>: <fpage>797</fpage>–<lpage>807</lpage>.<pub-id pub-id-type="pmid">22212116</pub-id></mixed-citation></ref><ref id="pone.0054890-Friesema1"><label>16</label><mixed-citation publication-type="journal"><name><surname>Friesema</surname><given-names>IH</given-names></name>, <name><surname>Meijer</surname><given-names>A</given-names></name>, <name><surname>van Gageldonk-Lafeber</surname><given-names>AB</given-names></name>, <name><surname>van der Lubben</surname><given-names>M</given-names></name>, <name><surname>van Beek</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Course of pandemic influenza A(H1N1) 2009 virus infection in Dutch patients</article-title>. <source>Influenza Other Respi Viruses</source><volume>6</volume>: <fpage>e16</fpage>–<lpage>20</lpage>.</mixed-citation></ref><ref id="pone.0054890-NIBSC1"><label>17</label><mixed-citation publication-type="other">NIBSC (2011) Available: <ext-link ext-link-type="uri" xlink:href="http://www.nibsc.ac.uk/documents/ifu/09-194.pdf">http://www.nibsc.ac.uk/documents/ifu/09-194.pdf</ext-link>.Accessed 2012 Jun 28.</mixed-citation></ref><ref id="pone.0054890-Jefferies1"><label>18</label><mixed-citation publication-type="other">Jefferies S, Earl D, Berry N, Blackmore T, Rooker S, <etal>et al</etal>.. (2011) Effectiveness of the 2009 seasonal influenza vaccine against pandemic influenza A(H1N1)2009 in healthcare workers in New Zealand, June-August 2009. Euro Surveill 16.</mixed-citation></ref><ref id="pone.0054890-Kelly1"><label>19</label><mixed-citation publication-type="other">Kelly H, Grant K (2009) Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill 14.</mixed-citation></ref><ref id="pone.0054890-Couch1"><label>20</label><mixed-citation publication-type="journal"><name><surname>Couch</surname><given-names>RB</given-names></name>, <name><surname>Atmar</surname><given-names>RL</given-names></name>, <name><surname>Franco</surname><given-names>LM</given-names></name>, <name><surname>Quarles</surname><given-names>JM</given-names></name>, <name><surname>Nino</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Prior Infections With Seasonal Influenza A/H1N1 Virus Reduced the Illness Severity and Epidemic Intensity of Pandemic H1N1 Influenza in Healthy Adults</article-title>. <source>Clin Infect Dis</source><volume>54</volume>: <fpage>311</fpage>–<lpage>317</lpage>.<pub-id pub-id-type="pmid">22075792</pub-id></mixed-citation></ref><ref id="pone.0054890-GarciaGarcia1"><label>21</label><mixed-citation publication-type="journal"><name><surname>Garcia-Garcia</surname><given-names>L</given-names></name>, <name><surname>Valdespino-Gomez</surname><given-names>JL</given-names></name>, <name><surname>Lazcano-Ponce</surname><given-names>E</given-names></name>, <name><surname>Jimenez-Corona</surname><given-names>A</given-names></name>, <name><surname>Higuera-Iglesias</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City</article-title>. <source>BMJ</source><volume>339</volume>: <fpage>b3928</fpage>.<pub-id pub-id-type="pmid">19808768</pub-id></mixed-citation></ref><ref id="pone.0054890-Johns1"><label>22</label><mixed-citation publication-type="journal"><name><surname>Johns</surname><given-names>MC</given-names></name>, <name><surname>Eick</surname><given-names>AA</given-names></name>, <name><surname>Blazes</surname><given-names>DL</given-names></name>, <name><surname>Lee</surname><given-names>SE</given-names></name>, <name><surname>Perdue</surname><given-names>CL</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Seasonal influenza vaccine and protection against pandemic (H1N1) 2009-associated illness among US military personnel</article-title>. <source>PLoS One</source><volume>5</volume>: <fpage>e10722</fpage>.<pub-id pub-id-type="pmid">20502705</pub-id></mixed-citation></ref><ref id="pone.0054890-Grebe1"><label>23</label><mixed-citation publication-type="journal"><name><surname>Grebe</surname><given-names>KM</given-names></name>, <name><surname>Yewdell</surname><given-names>JW</given-names></name>, <name><surname>Bennink</surname><given-names>JR</given-names></name> (<year>2008</year>) <article-title>Heterosubtypic immunity to influenza A virus: where do we stand?</article-title><source>Microbes Infect</source><volume>10</volume>: <fpage>1024</fpage>–<lpage>1029</lpage>.<pub-id pub-id-type="pmid">18662798</pub-id></mixed-citation></ref><ref id="pone.0054890-Fang1"><label>24</label><mixed-citation publication-type="journal"><name><surname>Fang</surname><given-names>Y</given-names></name>, <name><surname>Banner</surname><given-names>D</given-names></name>, <name><surname>Kelvin</surname><given-names>AA</given-names></name>, <name><surname>Huang</surname><given-names>SS</given-names></name>, <name><surname>Paige</surname><given-names>CJ</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Seasonal H1N1 infection induces cross protective pandemic H1N1 immunity through a CD8 independent, B cell dependent mechanism</article-title>. <source>J Virol</source><volume>86</volume>: <fpage>2229</fpage>–<lpage>2238</lpage>.<pub-id pub-id-type="pmid">22130540</pub-id></mixed-citation></ref><ref id="pone.0054890-Hillaire1"><label>25</label><mixed-citation publication-type="journal"><name><surname>Hillaire</surname><given-names>ML</given-names></name>, <name><surname>van Trierum</surname><given-names>SE</given-names></name>, <name><surname>Kreijtz</surname><given-names>JH</given-names></name>, <name><surname>Bodewes</surname><given-names>R</given-names></name>, <name><surname>Geelhoed-Mieras</surname><given-names>MM</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells</article-title>. <source>J Gen Virol</source><volume>92</volume>: <fpage>2339</fpage>–<lpage>2349</lpage>.<pub-id pub-id-type="pmid">21653752</pub-id></mixed-citation></ref><ref id="pone.0054890-Laurie1"><label>26</label><mixed-citation publication-type="journal"><name><surname>Laurie</surname><given-names>KL</given-names></name>, <name><surname>Carolan</surname><given-names>LA</given-names></name>, <name><surname>Middleton</surname><given-names>D</given-names></name>, <name><surname>Lowther</surname><given-names>S</given-names></name>, <name><surname>Kelso</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model</article-title>. <source>J Infect Dis</source><volume>202</volume>: <fpage>1011</fpage>–<lpage>1020</lpage>.<pub-id pub-id-type="pmid">20715930</pub-id></mixed-citation></ref><ref id="pone.0054890-Bodewes2"><label>27</label><mixed-citation publication-type="journal"><name><surname>Bodewes</surname><given-names>R</given-names></name>, <name><surname>Kreijtz</surname><given-names>JH</given-names></name>, <name><surname>Rimmelzwaan</surname><given-names>GF</given-names></name> (<year>2009</year>) <article-title>Yearly influenza vaccinations: a double-edged sword?</article-title><source>Lancet Infect Dis</source><volume>9</volume>: <fpage>784</fpage>–<lpage>788</lpage>.<pub-id pub-id-type="pmid">19879807</pub-id></mixed-citation></ref><ref id="pone.0054890-Bodewes3"><label>28</label><mixed-citation publication-type="journal"><name><surname>Bodewes</surname><given-names>R</given-names></name>, <name><surname>Fraaij</surname><given-names>PL</given-names></name>, <name><surname>Geelhoed-Mieras</surname><given-names>MM</given-names></name>, <name><surname>van Baalen</surname><given-names>CA</given-names></name>, <name><surname>Tiddens</surname><given-names>HA</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Annual vaccination against influenza virus hampers development of virus-specific CD8 T cell immunity in children</article-title>. <source>J Virol</source><volume>85</volume>: <fpage>11995</fpage>–<lpage>12000</lpage>.<pub-id pub-id-type="pmid">21880755</pub-id></mixed-citation></ref><ref id="pone.0054890-Bodewes4"><label>29</label><mixed-citation publication-type="journal"><name><surname>Bodewes</surname><given-names>R</given-names></name>, <name><surname>de Mutsert</surname><given-names>G</given-names></name>, <name><surname>van der Klis</surname><given-names>FR</given-names></name>, <name><surname>Ventresca</surname><given-names>M</given-names></name>, <name><surname>Wilks</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands</article-title>. <source>Clin Vaccine Immunol</source><volume>18</volume>: <fpage>469</fpage>–<lpage>476</lpage>.<pub-id pub-id-type="pmid">21209157</pub-id></mixed-citation></ref><ref id="pone.0054890-Gioia1"><label>30</label><mixed-citation publication-type="journal"><name><surname>Gioia</surname><given-names>C</given-names></name>, <name><surname>Castilletti</surname><given-names>C</given-names></name>, <name><surname>Tempestilli</surname><given-names>M</given-names></name>, <name><surname>Piacentini</surname><given-names>P</given-names></name>, <name><surname>Bordi</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza</article-title>. <source>Emerg Infect Dis</source><volume>14</volume>: <fpage>121</fpage>–<lpage>128</lpage>.<pub-id pub-id-type="pmid">18258091</pub-id></mixed-citation></ref><ref id="pone.0054890-Skowronski1"><label>31</label><mixed-citation publication-type="journal"><name><surname>Skowronski</surname><given-names>DM</given-names></name>, <name><surname>De Serres</surname><given-names>G</given-names></name>, <name><surname>Crowcroft</surname><given-names>NS</given-names></name>, <name><surname>Janjua</surname><given-names>NZ</given-names></name>, <name><surname>Boulianne</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Association between the 2008–09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada</article-title>. <source>PLoS Med</source><volume>7</volume>: <fpage>e1000258</fpage>.<pub-id pub-id-type="pmid">20386731</pub-id></mixed-citation></ref><ref id="pone.0054890-Skowronski2"><label>32</label><mixed-citation publication-type="journal"><name><surname>Skowronski</surname><given-names>DM</given-names></name>, <name><surname>Hottes</surname><given-names>TS</given-names></name>, <name><surname>McElhaney</surname><given-names>JE</given-names></name>, <name><surname>Janjua</surname><given-names>NZ</given-names></name>, <name><surname>Sabaiduc</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age</article-title>. <source>J Infect Dis</source><volume>203</volume>: <fpage>158</fpage>–<lpage>167</lpage>.<pub-id pub-id-type="pmid">21288814</pub-id></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B52 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000B52 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:3554683
|texte= Profiling of Humoral Response to Influenza A(H1N1)pdm09 Infection and Vaccination Measured by a Protein Microarray in Persons with and without History of Seasonal Vaccination
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:23365683" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |